<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Ipsc on Tenu Tech Brief</title>
    <link>https://cluster-site.onrender.com/tags/ipsc/</link>
    <description>Recent content in Ipsc on Tenu Tech Brief</description>
    <generator>Hugo -- 0.146.0</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 24 Feb 2026 06:05:55 +0000</lastBuildDate>
    <atom:link href="https://cluster-site.onrender.com/tags/ipsc/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>First-of-a-kind stem-cell therapies set for approval in Japan</title>
      <link>https://cluster-site.onrender.com/posts/first-of-a-kind-stem-cell-therapies-set-for-approval-in-japan/</link>
      <pubDate>Tue, 24 Feb 2026 00:39:20 +0000</pubDate>
      <guid>https://cluster-site.onrender.com/posts/first-of-a-kind-stem-cell-therapies-set-for-approval-in-japan/</guid>
      <description>• Japan&amp;rsquo;s health ministry grants conditional approval to two pioneering stem‑cell therapies, Amchepry and ReHeart. • Amchepry targets Parkinson&amp;rsquo;s disease using iPSC‑derived progeni</description>
    </item>
  </channel>
</rss>
